Sold as Juvisync. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Simvastatin; Sitagliptin Phosphate (sold as Juvisync), first approved Oct 7, 2011, with 1 new use approved and 0 published complete response letters.
| A Study on the Safety and Clinical Efficacy of Guominkang in the Treatment of Diabetic Kidney DiseaseDiabetic Kidney Disease (DKD), Type 2 Diabetes · Beijing University of Chinese Medicine | Phase 2 | Active, not recruiting | Oct 30, 2026 |
| Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes StudyCardiovascular Events, Type2 Diabetes · Brigham and Women's Hospital | — | Active, not recruiting | Feb 2, 2022 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Oct 7, 2011 | JuvisyncNDA 202343 · New combination | Merck Sharp Dohme | 10 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
